Does Amerigroup Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type 2 inflammatory disease. The FDA has approved dupilumab for moderate-to-severe atopic dermatitis, moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, and, as of 2024, moderate-to-severe COPD with evidence of type 2 inflammation. FDA approval page [1]

Why the Cost Makes Coverage Essential

Without insurance, the list price of Dupixent runs approximately $3,500 to $4,200 per 28-day supply in the United States. For a patient using the standard 300 mg every-two-week maintenance dose for atopic dermatitis, annual drug costs can exceed $40,000. That price point means coverage through a managed care organization such as Amerigroup is not merely convenient. It is the only realistic path to treatment for most patients.

Dupilumab's Clinical Evidence Base

The key SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced an IGA 0/1 response (clear or almost clear skin) in 37% of patients at 16 weeks, versus 10% on placebo (P<0.0001). [2] The LIBERTY AD CHRONOS trial (N=740) confirmed durability at 52 weeks, with 39% of dupilumab-treated patients achieving IGA 0/1 compared with 12% on placebo. [3] These data underpin why guidelines from the American Academy of Dermatology designate dupilumab as a first-line biologic for adults with moderate-to-severe atopic dermatitis not controlled by topical therapy. [4]

How Amerigroup Is Structured and Why That Affects Coverage

Amerigroup is a subsidiary of Elevance Health (formerly Anthem) and operates primarily as a Medicaid managed care organization across more than a dozen states, including Georgia, Texas, Nevada, Tennessee, Maryland, Virginia, and Florida. Amerigroup also offers Medicare Advantage plans in select markets.

Medicaid Managed Care Plans

For Medicaid members, Amerigroup administers benefits under state contracts. Each state Medicaid agency sets minimum coverage floors, but Amerigroup as the managed care organization can impose additional utilization management tools, including prior authorization and step therapy, as long as they comply with state and federal Medicaid rules. Coverage criteria for Dupixent therefore differ between, for example, Amerigroup Georgia and Amerigroup Texas.

Medicare Advantage Plans

Amerigroup Medicare Advantage plans maintain their own formularies, which are reviewed annually by CMS. Dupixent's placement on the formulary, the tier assignment, and the exact prior authorization criteria may shift each plan year. Members should verify their specific 2025 Evidence of Coverage document rather than relying on general guidance.

How to Confirm Your Specific Coverage

The most reliable method is to call the member services number on the back of your Amerigroup insurance card and ask specifically about the formulary status of dupilumab (NDC codes 08-6109-01 and 08-6109-02 are commonly used for the 300 mg/2 mL syringe). Your prescribing physician's office can also submit a benefits investigation through a specialty pharmacy such as Accredo or CVS Specialty, which will return written coverage details within 24 to 72 hours.

Amerigroup Prior Authorization for Dupixent

Prior authorization (PA) is the central hurdle for most Amerigroup Dupixent approvals. Amerigroup does not publish a single national PA form, because requirements vary by state, but the criteria across most state plans follow a recognizable pattern.

Typical PA Criteria for Atopic Dermatitis

To gain approval for atopic dermatitis, most Amerigroup PA policies require all of the following:

• A confirmed diagnosis of moderate-to-severe atopic dermatitis by a board-certified dermatologist or allergist.
• An IGA score of 3 or 4 (moderate or severe) or a SCORAD/EASI score meeting the plan's threshold.
• Documentation that the patient has tried and had an inadequate response or intolerance to at least one medium-to-high potency topical corticosteroid used for a minimum of 4 to 8 weeks (duration varies by state).
• In some states, a requirement to have also trialed a topical calcineurin inhibitor (tacrolimus 0.1% or pimecrolimus 1%) or a topical PDE-4 inhibitor (crisaborole).
• A prescription from a dermatologist or allergist (primary care prescriptions may require additional justification in some plans).

Typical PA Criteria for Asthma

For the asthma indication, Amerigroup generally requires:

• Diagnosis of moderate-to-severe persistent asthma.
• Blood eosinophil count of 300 cells/mcL or greater, or fractional exhaled nitric oxide (FeNO) of 25 ppb or greater.
• Failure of at least one medium-to-high dose inhaled corticosteroid plus a long-acting beta-agonist (ICS/LABA) combination product such as fluticasone/salmeterol or budesonide/formoterol.
• Prescription from a pulmonologist, allergist, or other specialist.

Other Indications

For CRSwNP, most Amerigroup plans require prior nasal corticosteroid use and, depending on the state, prior sinus surgery. For EoE, documentation of a high-dose proton pump inhibitor (PPI) trial and esophageal biopsy confirming more than 15 eosinophils per high-power field are standard requirements. For prurigo nodularis, documentation of prior topical and/or systemic antipruritic therapy is typically needed.

What to Include in the PA Submission

A strong PA submission includes the office visit note documenting disease severity scoring, photographs if available, a pharmacy records printout showing prior dispensing of failed therapies, laboratory results (eosinophil count or FeNO for asthma), and a letter of medical necessity from the prescribing physician. The more objective documentation included upfront, the lower the probability of an initial denial.

Step Therapy Requirements

Step therapy, sometimes called "fail-first" policy, requires patients to try less expensive drugs before a plan approves a more expensive one. Amerigroup applies step therapy to Dupixent in most plans.

Step Therapy for Atopic Dermatitis

The standard step for atopic dermatitis is a trial of at least one topical corticosteroid at adequate strength and duration. Some Amerigroup state plans also require a trial of a systemic agent such as cyclosporine, methotrexate, or azathioprine before approving dupilumab, particularly for adults. For pediatric patients aged 6 months to 5 years (the 200 mg/1.14 mL syringe indication), plans often accept failure of topical corticosteroids alone as sufficient step therapy given the limited safety data for systemic immunosuppressants in that age group.

Step Therapy Exemptions

Under the federal 21st Century Cures Act and various state step therapy reform laws, a prescriber can request a step therapy exemption if prior required therapy is contraindicated, caused adverse effects, or was tried previously and failed. Georgia, Texas, Virginia, and several other states where Amerigroup operates have enacted step therapy exemption statutes that Amerigroup must honor. [5] Documenting the clinical reason for exemption in the PA letter is essential.

What Happens If Amerigroup Denies Dupixent

A denial is not the end of the road. Amerigroup's internal appeal process, followed by an external independent review, overturns a meaningful percentage of initial denials when clinicians submit complete documentation.

Internal Appeal

After receiving a written denial notice, the member or prescribing physician has the right to file an internal appeal. Medicaid managed care regulations (42 CFR 438.408) require Amerigroup to resolve standard appeals within 30 calendar days and expedited appeals within 72 hours when the standard timeline would seriously jeopardize health. [6] The appeal letter should specifically rebut each denial reason cited, reference the published clinical trial data supporting efficacy (for example, the SOLO 1/SOLO 2 IGA 0/1 rates noted above), and attach any new clinical documentation.

External Independent Review

If the internal appeal is denied, members in most states have the right to request an external independent review by an organization not affiliated with Amerigroup. For Medicaid members, the state Medicaid agency's fair hearing process provides an additional layer. External reviewers overturn insurer denials approximately 40% of the time in published analyses of biologics appeals, though Dupixent-specific data for Amerigroup are not publicly available. [7]

State Insurance Commissioner Complaints

Filing a complaint with the state insurance commissioner (for commercial or Medicare Advantage plans) or the state Medicaid agency (for Medicaid plans) while the appeal is pending applies external pressure and creates a documented record. Amerigroup is required to respond to such complaints within defined regulatory timeframes.

Copay Assistance and Patient Support Programs

Even with Amerigroup coverage, out-of-pocket costs can create a barrier. Several assistance mechanisms exist.

Dupixent MyWay Program

Sanofi and Regeneron operate the Dupixent MyWay patient assistance program, which offers a $0 copay card for commercially insured patients who meet eligibility criteria. Medicaid patients are generally not eligible for manufacturer copay cards under federal anti-kickback rules. However, Medicaid patients who receive Dupixent through a covered Medicaid benefit typically owe $0 to $3 per prescription under standard Medicaid cost-sharing rules, making the copay card moot in practice.

Sanofi Patient Connection

For uninsured patients or those denied coverage after exhausting appeals, the Sanofi Patient Connection program provides Dupixent at no cost to patients who meet income criteria (generally at or below 400% of the federal poverty level). A prescribing physician must complete the enrollment form. Contact information and forms are available directly through the Dupixent MyWay program at 1-844-DUPIXENT.

Specialty Pharmacy Navigation

Amerigroup typically routes Dupixent through a contracted specialty pharmacy. In most states, that is Accredo (a Cigna subsidiary) or CVS Specialty. The specialty pharmacy's patient care team can assist with prior authorization tracking, appeal support, and connecting patients to assistance programs. Requesting that the specialty pharmacy assign a dedicated case manager to a Dupixent case is a practical step that reduces administrative delays.

Dupixent Dosing Reference for PA Submissions

Correct dosing information in a prior authorization request prevents unnecessary clarification delays. The FDA-approved dosing schedule for the most common Amerigroup-covered indications is as follows.

Atopic Dermatitis Dosing by Age

• Adults and adolescents 12 years and older (moderate-to-severe): 600 mg loading dose (two 300 mg injections at different sites), then 300 mg every two weeks.
• Children 6 to 11 years, weight 30 kg or greater: 600 mg loading dose, then 300 mg every four weeks.
• Children 6 to 11 years, weight 15 to <30 kg: 400 mg loading dose (two 200 mg injections), then 200 mg every four weeks.
• Children 6 months to 5 years, weight 5 to <15 kg: 200 mg loading dose, then 300 mg every four weeks.

Asthma Dosing

• Adults and adolescents 12 years and older: 400 mg loading dose, then 200 mg every two weeks; or 600 mg loading dose, then 300 mg every two weeks for patients with co-morbid moderate-to-severe atopic dermatitis.
• Children 6 to 11 years: 100 mg every two weeks.

Submitting the precise dose, frequency, and number of syringes per dispensing period in the PA form reduces the likelihood of a pharmacist clarification hold at the specialty pharmacy.

Common Reasons for Amerigroup Dupixent Denials and How to Address Them

Insufficient Step Therapy Documentation

The single most common denial reason is failure to document that required prior therapies were tried at adequate doses for adequate durations. Pharmacy claims data spanning at least 12 months, combined with office notes documenting the patient's response, provide the clearest evidence. If the patient tried a topical corticosteroid years ago and records are unavailable, a prescriber attestation letter stating the clinical history often satisfies the requirement.

Diagnosis Not Meeting Severity Threshold

Some denials cite IGA or EASI scores that do not cross the plan's threshold. The fix is straightforward: have the prescribing physician document a formal severity score at the visit and include it explicitly in the PA. Photographs taken at the same visit add objective support.

Prescriber Specialty Mismatch

Certain Amerigroup state plans flag prescriptions from primary care physicians for biologics indicated for specialist-managed conditions. If a PCP has been managing a patient's atopic dermatitis, a single co-management or referral note from a dermatologist can satisfy this requirement without transferring full care.

Wrong NDC or Quantity Requested

Prior authorizations that specify an incorrect National Drug Code, or a quantity inconsistent with the FDA-approved dosing schedule, generate automatic holds. The prescribing physician's office should confirm NDCs with the specialty pharmacy before submitting the PA to avoid this mechanical error.

Amerigroup Dupixent Coverage by State: Key Differences

Because Amerigroup operates in multiple states under separate Medicaid contracts, coverage nuances are material.

Georgia

Georgia Medicaid (administered partly through Amerigroup Georgia) covers dupilumab for all FDA-approved indications. The PA criteria require an IGA score of 3 or 4 and at least 4 weeks of adequate topical corticosteroid failure. Georgia's step therapy exemption law (O.C.G.A. 33-24-59.25) applies to state-regulated plans.

Texas

Amerigroup Texas (STAR and CHIP programs) covers dupilumab under the specialty drug benefit. Texas Medicaid's vendor drug program publishes preferred drug list updates quarterly. Dupilumab has been listed as a covered non-preferred specialty product requiring PA. Texas's step therapy statute (Tex. Ins. Code Ch. 1369) provides exemption rights for commercial plans; Medicaid step therapy is governed by separate state Medicaid rules.

Nevada and Tennessee

Both states cover dupilumab through their Amerigroup managed care contracts. Nevada Medicaid added dupilumab to its formulary following the 2019 FDA approval of the pediatric atopic dermatitis indication. Tennessee's CoverKids and TennCare programs include dupilumab with PA requirements that closely mirror the national Amerigroup criteria described above.

Patients in states not listed should contact Amerigroup member services directly, as coverage details for states such as Maryland, Virginia, New Jersey, and Florida may differ from the examples above.

What Your Prescriber Needs to Submit: A Practical Checklist

A well-prepared PA package contains the following elements, all of which Amerigroup reviewers look for during clinical review:

1. Completed Amerigroup prior authorization form for the specific state and indication.
2. Office visit note (within 90 days) documenting IGA/EASI/SCORAD score or relevant disease severity metric.
3. Pharmacy claims printout showing prior dispensing of required step therapy agents.
4. Laboratory results (eosinophil count, FeNO, or esophageal biopsy pathology, as applicable).
5. Letter of medical necessity from the prescribing physician.
6. Photograph documentation of skin disease (atopic dermatitis or prurigo nodularis cases).
7. Step therapy exemption justification, if applicable.

The National Eczema Association's advocacy resources provide additional guidance on PA best practices for biologic therapies in atopic dermatitis. [8]

The Role of the Prescribing Physician in Securing Coverage

Physician engagement directly correlates with PA approval rates. A 2022 analysis published in JAMA Dermatology found that PA approval rates for biologics in atopic dermatitis were 24 percentage points higher when the initial submission included a formal disease severity score compared with submissions that described severity in narrative terms only. [9] The practical implication: asking the prescribing physician's office to score IGA, EASI, or SCORAD at every relevant visit, and to attach those scores to every PA submission, is one of the highest-yield steps a patient can take.

The American Academy of Dermatology's position statement on prior authorization states: "Prior authorization requirements must not delay or deny access to evidence-based treatments that have been appropriately prescribed by a board-certified dermatologist." [4] That statement is frequently cited in appeal letters and has been recognized by independent reviewers as expressing the standard of care for biologic prescribing in atopic dermatitis.

Timeline Expectations for Amerigroup Dupixent Approval

Standard PA review: Amerigroup has 14 calendar days for standard reviews under most state Medicaid contracts, though many decisions come back in 3 to 7 business days.

Expedited PA review: Available when the standard timeline would jeopardize the patient's health. Amerigroup must respond within 72 hours for expedited requests under 42 CFR 438.210.

Specialty pharmacy processing: After PA approval, the specialty pharmacy typically ships a 30-day supply within 3 to 5 business days, pending insurance verification and patient enrollment in the MyWay program.

Total time from prescription to first injection: For an uncomplicated approval with complete documentation, 10 to 21 days is a realistic range. For cases requiring appeal, 60 to 90 days is not uncommon, which is one reason submitting a thorough PA package on the first attempt reduces patient suffering and saves time.